Table 2.
Patients with anti CD20 induced humoral immunosuppression and COVID-19 treated with convalescent plasma.
| Case | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9-23 | Patient 24* | Patient 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 66 | 62 | 53 | 76 | 54 | 40-60 | 63 | 53 | 58 [35–77] | 76 | 55 |
| Gender (M/F) | M | M | F | F | M | N.R. | F | F | 5F/12M | F | F |
| Date of administration of first convalescent plasma | 10-may-2020 | 3-jun-2020 | 27-apr-2020 | 14-may-2020 | 15-apr-2020 | N.R. | Jun-2020 | 20-jun-2020 | N.R. | 12-jun-2020 | 27-jun-2020. |
| Amount of plasma (ml) | 300 | 300 | 200 | 400 | 200 | N.R. | 200 | N.R. | 400 | 200 | N.R. |
| Date of administration of second convalescent plasma | 14-may-2020 | – | 6-may-2020 | 15-may-2020 | – | – | – | 5-jul-2020 | Next day | 13-jun-2020 | – |
| Amount of plasma (ml) | 300 | – | 200 | 400 | – | – | – | N.R. | 400 | 200 | – |
| Disease responsible of humoral immunosuppression | Mantle cell lymphoma, autologous SCT, ongoing rituximab maintenance | Follicular lymphoma, ongoing rituximab maintenance | B-cell acute lymphoblastic leukemia, allogeneic SCT, cGVHD ongoing rituximab maintenance | Marginal zone lymphoma, ongoing rituximab maintenance | Follicular lymphoma, ongoing rituximab maintenance | Mantle cell lymphoma, autologous SCT, ongoing rituximab maintenance | Non-Hodgkin lymphoma, ongoing obinutuzumab maintenance | Follicular lymphoma, ongoing obinutuzumab maintenance | 15 Hematological malignancies 1 Multiple Sclerosis 1 CVID |
Cjhronic lymphocytic leukemia, treated with rituximab-bendamustine | B-cell acute lymphoblastic leukemia, treated with rituximab, cytarabine and dasatinib |
| Adverse reactions | Mild decrease BOS, Fever | Mild decrease BOS | – | No | – | – | Mild decrease BOS | – | – | – | – |
| Days from first symptoms to plasma administration | 35 | 57 | 4 | 50 | 32 | 34 | 88 | 90 | 56 [7–83] | 66 | 80 |
| Days from first plasma administration to discharge/exitus | 7 | 1 | 11 | 19 | 7 | 24 | 2 | 2 | 7 [2–14] | 7 | Few days |
| Outcome | Favourable | Favourable | Favourable | Favourable | Favourable | Favourable | Favourable | Favourable | 16 Favourable/ 1 Exitus |
Favourable | Favourable |
| Reference | Current case 2 | Current case 3 | Ref. 33 | Ref. 34 | Ref. 35 | Ref. 36 | Ref. 37 | Ref. 38 | Ref. 21 | Ref. 39 | Ref. 40 |
Gender: M = Male, F = Female; N.R.: Not reported; STC: Stem cell transplant; cGVHD: Chronic Graf-versus-host disease; BOS: Baseline oxygen saturation.
Patients 9–23: Age, Days from first symptoms to plasma administration, Days from first plasma administration to discharge/exitus = median, range between brackets.
Patient 24 received 4 consecutive doses of 200 ml of CCP from 12th to 15th of June 2020.